Scrutinizing neuro-immune regulatory mechanisms underlying depressive symptomatology in young adults with HIV

仔细检查年轻艾滋病毒感染者抑郁症状背后的神经免疫调节机制

• 批准号: 10370250
• 负责人: Suzi Hong
• 金额: $ 19.75万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-10 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10370250
• 关键词: Adherence; Adrenal Glands; Adrenergic Receptor; Affect; Affective; Agonist; Anhedonia; Anisotropy; Anterior; Behavioral; Biological; Blood; Brain; Brain region; CD4 Positive T Lymphocytes; Caregivers; Cell Count; Cell model; Cell physiology; Choline; Clinical; Cognitive; Coupled; Data; Demographic Factors; Diffusion Magnetic Resonance Imaging; Etiology; Exploratory/Developmental Grant; Functional disorder; Future; Glucocorticoid Receptor; Glucocorticoids; HIV; HIV Infections; Health; Healthcare; High Prevalence; Immune; Individual; Inflammation; Inflammatory; Inositol; Investigation; Knowledge; Lead; Magnetic Resonance Spectroscopy; Major Depressive Disorder; Measures; Mediating; Mediator of activation protein; Mental Depression; Modality; Modeling; Mood Disorders; Moods; Morbidity - disease rate; Neurobiology; Neuroimmune; Neurons; Neurosecretory Systems; Participant; Pathway interactions; Plasma; Population; Quality of life; Regulation; Reporting; Research; Role; Structure; Symptoms; Time; Viral; Viral Load result; Youth; aged; brain pathway; clinically relevant; depressive symptoms; imaging biomarker; immune function; inflammatory marker; insight; marijuana use; monocyte; mortality; multimodality; neuroimaging; neuroimaging marker; neuroinflammation; peripheral blood; psychologic; psychosocial; receptor; response; sociodemographics; symptomatology; targeted treatment; therapeutic target; treatment adherence; white matter; young adult

Project Summary/Abstract Mood disorders are prevalent among individuals living with HIV for which multi-dimensional, contributing factors exist. Especially, 20-50% of youth living with HIV (YWH) report depression or elevated depressive symptoms of clinical relevance. Depression or elevated depressive symptoms in YWH result in HIV include poor adherence to HIV treatment, poor viral suppression, increased morbidity and mortality as well as decreased quality of life. In spite of growing data showing the association between blood inflammatory markers and levels of depressive mood or clinical depression in HIV- and HIV+ individuals, inconsistent findings across the studies in the inflammatory marker-depression associations pose challenges in understanding mechanisms and lead to a paucity of targeted therapeutics. Given the profound modulatory effects of multiple branches of the neuroendocrine system on immune/inflammatory activities, we propose to conduct simultaneous investigations of potentially concurrent but disparate neuro-immune pathways (“NIP”) of inflammation dysregulation (IR) in predicting depressive symptoms in 45 YWH and 45 Control youth (aged 18-25 yrs), by leveraging an ongoing R01 study of brain function and cannabis use in YWH (DA047906). We will employ an ex vivo cellular model of peripheral blood monocytes by which effects of various receptor agonists in cellular IR will be assessed [1) sympatho-adrenal (SA)/adrenergic receptor (AR); 2) glucocorticoid (GC)/GC receptor (GR), and 3) dopaminergic (DA)/DR pathways] in predicting depressive symptoms (Aim 1). The neuroimaging markers of neuroinflammation from R01 [1) diffusion tensor imaging measures (e.g., fractional anisotropy), 2) structural alterations (i.e., white matter abnormality), and 3) metabolites through MR Spectroscopy (i.e., higher choline and myo-inositol, indicating diminished neuronal integrity and increased inflammation)] will be examined as a mediator (Aim 2). We will also explore differing depressive symptom domains [1) cognitive, 2) affective, and 3) somatic domains as well as 4) apathy and 5) anhedonia], as initial evidence shows symptoms specific to HIV infection such as somatic symptoms and apathy which may provide insight into delineating NIP- brain regions-symptoms network (Aim 3). Many types of the data collected in the R01 study will be shared with this R21 such as sociodemographic; clinical; psychological and behavioral; and neuroimaging data, maximizing the feasibility of this R21. Our simultaneous investigation of three NIP pathways with careful analytical plans in predicting depressive symptoms will provide an opportunity to gain mechanistic knowledge beyond plasma inflammatory marker-depression associations and to inform targeted therapeutic modalities.

项目总结/摘要 情绪障碍在艾滋病毒感染者中普遍存在， 因素存在。特别是，20-50%的青年艾滋病毒感染者（YWH）报告抑郁症或抑郁程度升高， 临床相关症状。抑郁或抑郁症状加重导致艾滋病毒感染的YWH包括 艾滋病毒治疗坚持性差，病毒抑制效果差，发病率和死亡率增加，以及 生活质量下降。尽管越来越多的数据显示血液炎症标志物 以及HIV-和HIV+个体的抑郁情绪或临床抑郁水平， 炎症标志物与抑郁症相关性的研究对理解其机制提出了挑战 并导致靶向治疗药物的缺乏。考虑到神经系统多个分支的深刻调节作用， 神经内分泌系统对免疫/炎症活动的影响，我们建议同时进行 炎症的潜在并发但不同的神经免疫途径（“NIP”）的研究 在45名YWH和45名对照青年（年龄18-25岁）中预测抑郁症状的调节障碍（IR）， 利用正在进行的R 01研究YWH的脑功能和大麻使用（DA 047906）。我们将雇用一名 外周血单核细胞的离体细胞模型，通过该模型，各种受体激动剂在细胞IR中的作用 将评估[1）交感-肾上腺（SA）/肾上腺素能受体（AR）; 2）糖皮质激素（GC）/GC受体 (GR)和3）多巴胺（DA）/DR通路]预测抑郁症状（目的1）。神经成像 来自R 01的神经炎症标志物[1]扩散张量成像测量（例如，分数各向异性），2） 结构改变（即，白色物质异常），和3）通过MR光谱的代谢物（即，更高 胆碱和肌醇，表明神经元完整性降低和炎症增加）]将被 作为一个调解人（目标2）。我们还将探讨不同的抑郁症状领域[1）认知，2） 情感，和3）躯体领域以及4）冷漠和5）快感缺乏]，作为初步证据显示的症状 艾滋病毒感染特有的症状，例如躯体症状和冷漠，这可能为划定NIP提供见解- 脑区-症状网络（Aim 3）。R 01研究中收集的许多类型的数据将与 这种R21，如社会人口统计学;临床;心理和行为;和神经成像数据，最大化 R21的可行性。我们同时调查了三个NIP途径，并制定了详细的分析计划， 预测抑郁症状将提供一个机会，获得机械知识超越血浆 炎症标志物-抑郁症的关联，并告知有针对性的治疗方式。